vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Waterstone Financial, Inc. (WSBF). Click either name above to swap in a different company.

Waterstone Financial, Inc. is the larger business by last-quarter revenue ($37.2M vs $19.6M, roughly 1.9× STANDARD BIOTOOLS INC.). On growth, Waterstone Financial, Inc. posted the faster year-over-year revenue change (16.7% vs -11.5%). Waterstone Financial, Inc. produced more free cash flow last quarter ($23.0M vs $-23.1M). Over the past eight quarters, Waterstone Financial, Inc.'s revenue compounded faster (7.1% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Waterstone Financial, Inc. is a U.S. bank holding company headquartered in Wisconsin. It offers retail and commercial banking services, residential mortgages, and wealth management solutions, primarily serving consumers and small to medium-sized businesses across the U.S. Midwest region.

LAB vs WSBF — Head-to-Head

Bigger by revenue
WSBF
WSBF
1.9× larger
WSBF
$37.2M
$19.6M
LAB
Growing faster (revenue YoY)
WSBF
WSBF
+28.2% gap
WSBF
16.7%
-11.5%
LAB
More free cash flow
WSBF
WSBF
$46.1M more FCF
WSBF
$23.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
WSBF
WSBF
Annualised
WSBF
7.1%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
WSBF
WSBF
Revenue
$19.6M
$37.2M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
27.0%
Net Margin
-177.4%
Revenue YoY
-11.5%
16.7%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WSBF
WSBF
Q4 25
$37.2M
Q3 25
$19.6M
$37.0M
Q2 25
$21.8M
$38.0M
Q1 25
$40.8M
$29.7M
Q4 24
$31.8M
Q3 24
$22.1M
$34.1M
Q2 24
$22.5M
$37.2M
Q1 24
$45.5M
$32.4M
Net Profit
LAB
LAB
WSBF
WSBF
Q4 25
Q3 25
$-34.7M
$7.9M
Q2 25
$-33.5M
$7.7M
Q1 25
$-26.0M
$3.0M
Q4 24
Q3 24
$-26.9M
$4.7M
Q2 24
$-45.7M
$5.7M
Q1 24
$-32.2M
$3.0M
Gross Margin
LAB
LAB
WSBF
WSBF
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
WSBF
WSBF
Q4 25
27.0%
Q3 25
-168.5%
26.6%
Q2 25
-118.1%
25.4%
Q1 25
-80.8%
13.1%
Q4 24
19.5%
Q3 24
-120.9%
17.3%
Q2 24
-134.5%
19.2%
Q1 24
-132.2%
14.7%
Net Margin
LAB
LAB
WSBF
WSBF
Q4 25
Q3 25
-177.4%
21.4%
Q2 25
-153.7%
20.3%
Q1 25
-63.8%
10.2%
Q4 24
Q3 24
-122.0%
13.9%
Q2 24
-203.3%
15.4%
Q1 24
-70.6%
9.4%
EPS (diluted)
LAB
LAB
WSBF
WSBF
Q4 25
$0.43
Q3 25
$-0.09
$0.45
Q2 25
$-0.09
$0.43
Q1 25
$-0.07
$0.17
Q4 24
$0.28
Q3 24
$-0.07
$0.26
Q2 24
$-0.12
$0.31
Q1 24
$-0.27
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WSBF
WSBF
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
$412.3M
Stockholders' EquityBook value
$399.7M
$349.4M
Total Assets
$539.6M
$2.3B
Debt / EquityLower = less leverage
1.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WSBF
WSBF
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
WSBF
WSBF
Q4 25
$412.3M
Q3 25
$469.1M
Q2 25
$465.7M
Q1 25
$395.9M
Q4 24
$446.5M
Q3 24
$55.2M
$560.1M
Q2 24
$55.1M
$660.8M
Q1 24
$55.0M
$634.2M
Stockholders' Equity
LAB
LAB
WSBF
WSBF
Q4 25
$349.4M
Q3 25
$399.7M
$345.5M
Q2 25
$424.5M
$341.5M
Q1 25
$454.6M
$341.4M
Q4 24
$339.1M
Q3 24
$489.3M
$342.0M
Q2 24
$510.3M
$334.9M
Q1 24
$577.3M
$338.0M
Total Assets
LAB
LAB
WSBF
WSBF
Q4 25
$2.3B
Q3 25
$539.6M
$2.3B
Q2 25
$557.0M
$2.3B
Q1 25
$579.6M
$2.2B
Q4 24
$2.2B
Q3 24
$681.5M
$2.2B
Q2 24
$708.7M
$2.3B
Q1 24
$777.7M
$2.2B
Debt / Equity
LAB
LAB
WSBF
WSBF
Q4 25
1.18×
Q3 25
1.36×
Q2 25
1.36×
Q1 25
1.16×
Q4 24
1.32×
Q3 24
0.11×
1.64×
Q2 24
0.11×
1.97×
Q1 24
0.10×
1.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WSBF
WSBF
Operating Cash FlowLast quarter
$-22.2M
$24.2M
Free Cash FlowOCF − Capex
$-23.1M
$23.0M
FCF MarginFCF / Revenue
-118.1%
61.9%
Capex IntensityCapex / Revenue
4.5%
3.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$43.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WSBF
WSBF
Q4 25
$24.2M
Q3 25
$-22.2M
$32.7M
Q2 25
$-20.7M
$-38.4M
Q1 25
$-30.3M
$26.7M
Q4 24
$48.1M
Q3 24
$-27.9M
$74.1M
Q2 24
$-39.0M
$-39.5M
Q1 24
$-62.5M
$-9.9M
Free Cash Flow
LAB
LAB
WSBF
WSBF
Q4 25
$23.0M
Q3 25
$-23.1M
$32.4M
Q2 25
$-22.6M
$-38.5M
Q1 25
$-35.3M
$26.5M
Q4 24
$47.0M
Q3 24
$-30.1M
$73.9M
Q2 24
$-41.0M
$-39.7M
Q1 24
$-63.3M
$-10.3M
FCF Margin
LAB
LAB
WSBF
WSBF
Q4 25
61.9%
Q3 25
-118.1%
87.5%
Q2 25
-103.6%
-101.2%
Q1 25
-86.6%
89.2%
Q4 24
147.5%
Q3 24
-136.4%
216.9%
Q2 24
-182.2%
-106.7%
Q1 24
-138.9%
-31.9%
Capex Intensity
LAB
LAB
WSBF
WSBF
Q4 25
3.1%
Q3 25
4.5%
0.8%
Q2 25
8.7%
0.2%
Q1 25
12.4%
0.9%
Q4 24
3.5%
Q3 24
10.2%
0.6%
Q2 24
8.6%
0.4%
Q1 24
1.7%
1.2%
Cash Conversion
LAB
LAB
WSBF
WSBF
Q4 25
Q3 25
4.13×
Q2 25
-4.98×
Q1 25
8.81×
Q4 24
Q3 24
15.67×
Q2 24
-6.92×
Q1 24
-3.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

WSBF
WSBF

Segment breakdown not available.

Related Comparisons